|
|
 |
|
Viewing report
|
|
|
|
Cancer Pancreatic Cancer
Life Science Analytics, March 2008, Pages: 194
'Cancer Pancreatic Cancer ' contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as well as a summary of the latest news and developments in this area.
Scope of the report:
Each ’ Therapy Area Pipeline Report provides the user with real detail on drug pipelines, by company and by stage, for each specific therapy area. The latest news, by company, also ensures that each report is fresh and up-to-date.
In addition to new developments and disease specific pipeline projects, each report also contains extensive information in tabular format on a company’s full product pipeline and products by phase of development with regard to the therapy area.
Full pipeline details, by stage, are provided and include detailed product descriptions, information on partnering activity plus clinical trial intelligence. Each Therapy Area Pipeline Report also provides detail on the top 20 companies with products in the early stage of development and the top 20 companies with products in the late stage of development. Finally, each report also provides a comparison with other major indications in the disease hub based on Marketed Products vs. Pipeline Products.
Key benefits
- Understand a company’s strategic position by accessing detailed independent intelligence on its product pipeline for specific therapy areas.
- Keep track of your competitors and partners by better understanding their product pipeline.
- Monitor a company’s research effectiveness by determining pipeline depth and number of products in development by clinical phase for specific disease areas.
- Maintain a critical competitive advantage.
Customers who bought this item also bought
Pancreatic Cancer Therapy Area Pipeline Report
Target Product Profiles 2008: Physician Insights on Key Attributes - Pancreatic Cancer (Advanced)
Niche Cancers 2001: Pancreatic Cancer
Stakeholder Opinions: Pancreatic Cancer - Gemzar Dominance will Continue among High Levels of Persistent Unmet Needs
Pancreatic Cancer - Gold Standard Gemcitabine Waiting to be Challenged
Strategic Perspectives: Pancreatic Cancer - Gemcitabine Combination Therapy is the Future
Pancreatic Cancer Drug Pipeline Report
Pancreatic Cancer Drug Pipeline Update 2008
The Cancer Market Outlook to 2012
Cancer Biomarkers: New Tools for Transforming Cancer Management
Global Cancer Focus Company Directory
The Spanish Cancer Diagnostics Market
|
|
|
|
